BioSpace News Archive

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the 2020 Jefferies Virtual Healthcare Conference on June 2, 2020, at 1:30 p.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay

Freenome , a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection with a routine blood draw, announced several new developments: initiating its PREEMPT CRC clinical trial; adding Gary Reedy, CEO of the American

Lucence Shares Data at ASCO20 Demonstrating High Sensitivity of AmpliMARK™ Sequencing Technology in Detecting Clinically Relevant Biomarkers in Lung Cancer CHICAGO--( BUSINESS WIRE )-- Coinciding with ASCO20, precision oncology company Lucence will be presenting data this week demonstrating high sensitivity of its liquid biopsy technology in detecting clinically relevant biomarkers in lung cancer, alongside promising data in breast and blood cancers. The dat

Nucleix , a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced that it will present data from ongoing research using a blood-based methylation assay for cancer detection during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program held May 29-31, 2020. The six-marker assay serves as an initial component of Nucleix’s screening

DSG, Inc. is supporting two Phase 3 studies sponsored by Romark, L.C. to evaluate an investigational new drug for prevention of COVID-19 in elderly residents of long-term care facilities and healthcare workers. Given the urgent nature of the COVID-19 pandemic, getting a trial up and running fast is crucial but even more critical is to build a trial that is adaptive with all the uncertainties and challenges of the curr

BioDuro, LLC, a leading drug discovery and development services organization, announced today the availability of two new preclinical models for Non-alcoholic steatohepatitis (NASH) that highly resemble clinical progression of the disease and do so in a matter of 2-3 months.

Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe- and needle-based confocal laser endomicroscopy (pCLE/nCLE) platform, today announced that the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Technology and Value Assessment Committee (TAVAC) published a review on the safety and efficacy of confocal laser endomicroscopy as a diagnostic tool for the evaluation of gastrointestinal pathologies.

Scientists from the J. Craig Venter Institute (JCVI), Icahn School of Medicine at Mount Sinai, and Pontificia Universidad Católica de Chile examined changes in the upper respiratory tract (URT) microbiome during an influenza A virus (IAV) infection.

Principia Biopharma Inc. announced upcoming presentations at the European Hematology Association and the International Society on Thrombosis and Haemostasis congresses from Principia’s clinical program evaluating rilzabrutinib in patients with immune thrombocytopenia, a rare autoimmune disease that causes high risk for bleeding, excessive bruising, fatigue and potential for life threatening intracranial bleeding due to destruction of platelets.

Quotient Limited, a commercial-stage diagnostics company, announced that financial results for its fiscal fourth quarter and full year ended March 31, 2020 will be released before market open on Tuesday, June 9, 2020.